NovoSorb® BTM Synthetic Wound Matrix Launches at MEDICA

NovoSorb BTM

PolyNovo UK Ltd officially launch its NovoSorb® BTM synthetic dermal scaffold at MEDICA 2021 in November.

Background

Surgical and traumatic wound care is never far from our pages.

Skin trauma can result in large portions of the surface of epidermis and dermis being destroyed. PolyNovo has designed a novel BTM technology to temporarily close the wound and aid the body in generating new tissue. The revolutionary biodegradable temporising matrix works by compartmentalising a large wound into a series of interconnected microwounds. This makes it easier for healing process, says the company.

About NovoSorb Wound Matrix Technology

Clinicians use NovoSorb BTM (Biodegradable Temporising Matrix) to treat complex wounds and burns where there has been a significant loss of tissue. PolyNovo invented and developed the product using polymer technology originating from CSIRO (Commonwealth Science Industry Research Organization).

BTM is indicated for full thickness and deep dermal wounds. These include traumatic injuries, burns, necrotising soft tissue infections and chronic wounds. It enables the generation of a vascularised neodermis. This provides a more robust foundation for wound reconstruction than grafting alone. The product’s developers designed it to limit wound scarring and contracture. As a result it provides an alternative option to lengthy, complex free-flap surgery. In addition, the technology is uniquely synthetic, so provides no substrate for bacterial growth. Indeed it has been shown to be robust in the presence of infection.

Founded in 2004, PolyNovo developed and patented its NovoSorb® polymer technology in order to fulfil the need for a synthetic biodegradable product that could be safely used in medical devices.

NovoSorb BTM was the first commercial offering from PolyNovo. It is already available for use in many countries throughout the world. The device was granted CE mark approval for sale throughout UK/Ireland and the European Union at the end of 2019. The company is now looking forward to expanding its footprint across Europe by exhibiting on the ABHI UK Pavilion at MEDICA 2021. They will also be launching a new smaller size of the device, which is indicated for diabetic foot ulcers and venous leg ulcers.

Company comments

PolyNovo’s Managing Director, Paul Brennan, said: “We were thrilled to announce our expansion into Europe in 2020. Following the travel restrictions this past year this is the first chance we will have to exhibit the unique BTM dermal template to a wider audience. We are delighted at the opportunity to demonstrate our innovation within the globally trusted ABHI brand at MEDICA 2021. We’re looking forward to connecting with new distributors to extend its benefits to more patients across Europe and worldwide. Our vision is always to support improved patient care using the power of our disruptive NovoSorb technology in the treatment of complex wounds.”

ABHI comments

Paul Benton, Managing Director, International at the ABHI added: “We are delighted that PolyNovo has chosen to launch their pioneering technology on the ABHI Pavilion. As a company they embody the power of innovation and its importance within healthcare. We look forward to supporting them in their goals to expand and bring the benefits of their revolutionary device to more patients globally.”

MEDICA, 15 – 18 November 2021. PolyNovo UK Ltd will be located on the ABHI UK Pavilion – Hall 16 Stand K42.

Source: PolyNovo UK Ltd.

Share your thoughts

Your email address will not be published. Required fields are marked *